Research collaboration announced between Oxford University and GSK
Natalia Elliot | January 27, 2025 | News story | Research and Development | Cancer, Oncology, Oxford University, neoantigens, partnership, research and development
The GSK-Oxford Cancer Immuno-Prevention Programme was announced at the end of January and will focus on researching the prevention of cancer through vaccination. The programme is an additional development to the existing relationship between Oxford University and GSK, including the GSK-Oxford Institute of Molecular and Computational Medicine in Oxford, UK.
“We’re pleased to further strengthen our relationship with Oxford University and to combine the deep knowledge of Oxford and GSK scientists. By exploring precancer biology and building on GSK’s expertise in the science of the immune system, we aim to generate key insights for people at risk of developing cancer,” stated Tony Wood, chief scientific officer at GSK.
Oxford University brings world-leading research into the study of precancer biology, which includes a study identifying neoantigens, which are tumour-specific proteins that prompt the immune system to recognise cancer. In addition to identifying them, the study also researched the sequencing of neoantigens. GSK has pledged to up to £50m over a minimum of three years to support research in the programme.
Professor Irene Tracey, vice-chancellor of the University of Oxford, UK, said: “This partnership represents a step forward in cancer research. By working with GSK to unite experts in clinical trials, immuno-oncology, vaccinology and precancer research from across the University of Oxford, we aim to unlock the potential of cancer vaccines and bring hope to patients worldwide.”
Natalia Elliot
27/1/25
Related Content
PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …
Central nervous system cancer metastases – the evolution of diagnostics and treatment
The current forms of immunotherapy, how T cell therapy works and what the future holds
Boehringer Ingelheim and LEO Pharma partner to develop treatment for generalised pustular psoriasis
Boehringer Ingelheim and LEO Pharma have partnered to commercialise and further develop Spevigo (spesolimab), a …
